BRCA1 and cancer: Based on the encouraging antitumor activity, many in whom had BRCA1/2 mutations, the trial was subsequently expanded to concentrate on cancers in patients with BRCA mutations and was presented in 2008 by Fong et al. [26], followed by publication of the manuscript in 2009 [27].